Phase III
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Several biopharmaceutical companies have submitted NDAs to the U.S. FDA covering treatment indications ranging from an opioid overdose, bipolar disorder and rare disease.
Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.
The U.S. FDA scolded CytoDyn for misrepresenting its clinical trial results for Leronlimab in COVID-19. Here’s what FDA has to say regarding CytoDyn Leronlimab.
The use of ruxolitinib cream, Incyte’s investigational anti-inflammatory JAK inhibitor topical treatment, significantly improved facial vitiligo in adolescents and adults.
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
A platform trial is also efficient in that it enables the investigators to share placebo information.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
Humanigen reported it had held a meeting with the FDA to discuss plans for filing an EUA for its lenzilumab for hospitalized, hypoxic COVID-19 patients by the end of May.
PRESS RELEASES